Welcome to our dedicated page for NYXOAH S A SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage med-tech companies like Nyxoah pack decades of R&D spending, Genio implant trial data, and regulatory milestones into hundreds of SEC pages—tough terrain when you only need answers about cash runway or FDA progress.
Stock Titan turns that problem on its head. Our AI parses every Nyxoah quarterly earnings report 10-Q filing, annual report 10-K, and 8-K material events the moment they hit EDGAR, then surfaces plain-English summaries, key risk flags, and Genio clinical-trial updates in seconds. Want to monitor Nyxoah insider trading Form 4 transactions? Real-time alerts spotlight each executive purchase or sale, so you can spot confidence shifts before the market reacts.
Use cases span the full disclosure set:
- Follow R&D expense trends and enrollment targets directly from 10-Q notes—Nyxoah earnings report filing analysis made easy.
- Compare device-safety discussions in the latest 10-K—Nyxoah annual report 10-K simplified by AI.
- Receive instant notifications for Nyxoah Form 4 insider transactions real-time and proxy updates on executive compensation.
- Understand how each Nyxoah 8-K material events explained might affect clinical timelines.
No more hunting through exhibits—understanding Nyxoah SEC documents with AI means spending minutes, not hours, to uncover what matters: Genio commercialization updates, segment revenue, and Nyxoah executive stock transactions Form 4. All filings, all the time, already decoded.
Nyxoah SA is offering 1,215,964 ordinary shares at $4.6304 (€4.00) per share, raising gross proceeds of about $5.6 million and estimated net proceeds of $5.5 million (€4.8 million). The shares are sold directly to investors without an underwriter, and trade on Nasdaq and Euronext Brussels under “NYXH.” Nyxoah plans to use the cash to support the U.S. launch and international commercialization of its Genio system for obstructive sleep apnea, fund clinical data generation and physician-led studies, advance R&D, build a pipeline in OSA monitoring and diagnostics, and for general corporate purposes.
Alongside this deal, the company has arranged a €17.0 million private placement of 4,265,714 ordinary shares at €4.00 and a separate offering of up to €45.0 million in amortizing senior unsecured convertible notes, expected to yield about €41.4 million in gross proceeds. As of September 30, 2025, Nyxoah had 37,544,782 ordinary shares outstanding, which would increase to 38,760,746 after this offering, before giving effect to the private placement, notes conversion, or warrant exercises.
Nyxoah SA announced a multi-part financing to support commercialization of its Genio system and ongoing R&D. The company agreed to a private placement of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million, expected to close on or about November 18, 2025, subject to customary conditions.
Separately, Nyxoah entered a registered direct offering of ordinary shares at U.S.$4.6304 per share for aggregate gross proceeds of approximately U.S.$5.6 million, also expected to close on or about November 18, 2025. In addition, the company signed a convertible notes deal for up to €45.0 million aggregate principal amount at an 8.0% original issue discount, issued in two €22.5 million tranches; assuming both tranches, gross proceeds total approximately €41.4 million. The notes bear 6.5% interest, mature three years from issuance, and amortize quarterly over 12 installments, with optional share-settled payments priced per the bond instrument. Initial conversion pricing is set at 125% of the private placement price for the first tranche.
Proceeds across the transactions are designated for U.S. and ex-U.S. commercialization, clinical data, R&D and cost reductions, pipeline and collaborations, and general corporate purposes.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
